Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular features influencing clinical outcome of advanced HER2-positive gastric cancer receiving trastuzumab plus chemotherapy.

Annals of medicine - 1 Dec 2025

Lei Yu, He Danxi, Si Jiqing, Yan Junrong, Yuan Minchi

Abstract excerpt

BACKGROUND: Less than half of the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) patients respond to trastuzumab plus chemotherapy, and the outcomes are unsatisfactory. Understanding the underlying mechanisms remains crucial for identifying patients who are more likely to benefit from treatment. PATIENTS AND METHODS: We performed targeted DNA sequencing on paired pre-treatment and...

Read the complete abstract on PubMed

Topics

Humans
Stomach Neoplasms
Trastuzumab
Erb-b2 Receptor Tyrosine Kinases
Female
Middle Aged
Male

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Antineoplastic Combined Chemotherapy Protocols

Aged

Adult

Progression-Free Survival

Mutation

Treatment Outcome

Gene Amplification

Poly-ADP-Ribose Binding Proteins

Antineoplastic Agents, Immunological

Source

Open in PubMed Open full text

Identifiers

PMID: 41195584
DOI: 10.1080/07853890.2025.2581815
PMCID: PMC12599165

Genes

GC
MYC
TOP2A

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular features influencing clinical outcome of advanced HER2-positive gastric cancer receiving trastuzumab plus chemotherapy.PMID 41195584Read ↗

Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapySemantic proximity Read ↗

Genomic correlations for clinical outcomes in HER2-positive advanced gastric cancers treated using trastuzumab-based therapySemantic proximity Read ↗

Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with TrastuzumabSemantic proximity Read ↗

The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer.Semantic proximity Read ↗

Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancerSemantic proximity Read ↗

Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.Semantic proximity Read ↗

Genomic characterization between HER2-positive and negative gastric cancer patients in a prospective trial.Semantic proximity Read ↗

Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2‐targeted therapiesSemantic proximity Read ↗

First-line pembrolizumab, trastuzumab, and chemotherapy in advanced HER2-positive gastric cancer with sequential genomic profilingSemantic proximity Read ↗

Difference of molecular alterations in HER2-positive and HER2-negative gastric cancers by whole-genome sequencing analysisSemantic proximity Read ↗

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast CancerSemantic proximity Read ↗

High tumor mutation burden in a patient with metastatic gastric cancer sensitive to trastuzumab: a case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.